

Excellence in Animal Health

& Bimeda

KEFAMAST LC

Cefalexin Dihydrostreptomycin

BENEFITS

- Broad spectrum antimicrobial activity
 against all major mastitis pathogens
- Excellent synergistic activity against acute and chronic mastitis
- Unique formulation with 2 powerful antibiotics, Cefalexin and Dihydrostreptomycin

PACKAGING

LIST NO.	UNIT PACKAGE	CASE SIZE
1KEF010	24	1

KEFAMAS

See reverse side for full indications, administration and dosage.



Bimeda[®] a division of Cross Vetpharm Group Ltd.

Broomhill Road I Tallaght I Dublin 24 I Ireland Tel: +353 1 4667900 Fax: +353 1 4515803 Web: www.bimedaexports.com



Excellence in Animal Health

KEFAMAST LACTATING COW

Presentation

Intramammary infusion, lactating cow. Each 9 g contains: Cefalexin (anhydrous) 500 mg Dihydrostreptomycin 500 mg (as Dihydrostreptomycin Sulphate)

Uses

For the treatment of mastitis caused by organisms susceptible to the combination of Cefalexin and Dihydrostreptomycin in lactating cows.

Dosage and Administration

The contents of one injector should be infused into each affected quarter, via the teat canal, immediately after milking and at twelve hourly intervals for a total of up to 3 infusions.

Before the infusion is made, the teat should be thoroughly cleaned and disinfected. Care should be taken to avoid contamination of the injector nozzle after the cap has been removed.

Contra-indications, Warnings, etc.

For animal treatment only.

Not to be used in animals known to be hypersensitive to the active ingredients.

Operator Warnings

Operators should avoid contact with this preparation as occasional skin allergy may occur.

Penicillins and cephalosporins may cause

hypersensitivity following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa.

Allergic reactions to these substances may occasionally be serious.

Do not handle this product if you know that you are sensitized, or if you have been advised not to work with such preparations.

Handle this product with care to avoid exposure. If you develop symptoms such as a skin rash following exposure, seek medical advice and show this warning to the doctor. Swelling of the face, lips or eyes, or difficulty breathing are more serious symptoms and require urgent medical attention.

Withdrawal Periods

Milk for human consumption must not be taken from cows during treatment. With cows milked twice daily, milk for human consumption may only be taken from 96 hours (i.e. at the eighth milking) after the last treatment. Animals should not be slaughtered for human consumption during treatment. Cows may be slaughtered for human consumption only after 7 days following the last treatment.

Pharmaceutical Precautions

Keep out of reach and sight of children. Store below 25°C. This product does not contain a preservative. Avoid the introduction of contamination during use. For single use only.

Unused product or waste material should be disposed of in accordance with current practice for pharmaceutical waste under national waste disposal regulations.

Legal Category POM

Package Quantities

Cartons of 24 syringes.

VPA 10126/33/1

This information should be used as a general guide, for more specific instructions on the use of Bimeda $^\circ$ products always read the product label carefully.



Bimeda® a division of Cross Vetpharm Group Ltd.

Broomhill Road I Tallaght I Dublin 24 I Ireland Tel: +353 1 4667900 Fax: +353 1 4515803 Web: www.bimedaexports.com